CureSeq to Offer Rapid NGS Tumor Profiling Services; Conducting Clinical Trials with Chinese Partners | GenomeWeb

This article has been updated with additional information from CureSeq.

NEW YORK (GenomeWeb) – CureSeq of Brisbane, California is gearing up to offer targeted next-gen sequencing-based tumor profiling services that it said will be fast and affordable. The company, a spinout from the University of California, San Francisco, has been selling reagent kits for FFPE DNA extraction and three NGS cancer panels and is currently waiting for CLIA certification of its laboratory.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.